propranolol and Ache
propranolol has been researched along with Ache in 80 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " In intention-to-treat and per-protocol analyses, patients randomized to propranolol had worse pain scores on study days 5 to 19." | 9.20 | Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury. ( Bangdiwala, SI; Bortsov, AV; Cairns, BA; Haith, LR; Halawa, OI; Holmes, JH; Hoskins, JM; Hwang, J; Jones, SW; Jordan, MH; McLean, SA; Orrey, DC; Platts-Mills, TF; Roane, BR; Shupp, JW, 2015) |
| "Propranolol significantly decreased perceived intensity of heat pain stimuli but only in participants with small propranolol-induced blood pressure decreases." | 9.17 | Effects of intravenous propranolol on heat pain sensitivity in healthy men. ( Abulhasan, YB; Alhujairi, M; Balderi, T; Carli, F; Kim, DJ; Koeva, V; Schweinhardt, P, 2013) |
| "The number of patients reporting a reduction in pain intensity rating was greater during propranolol treatment (P=0." | 9.14 | Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. ( Diatchenko, L; Lim, PF; Maixner, W; McLean, SA; Slade, GD; Smith, SB; Tchivileva, IE, 2010) |
| "Serum propranolol concentration, elimination t 1/2, and protein binding were studied after a combined intravenous/oral regimen in 20 subjects with myocardial infarction (MI) and 15 with chest pain (CP)." | 7.67 | Propranolol disposition after acute myocardial infarction. ( Norris, RM; Paxton, JW, 1984) |
| "Propranolol was administered intravenously to 12 patients with presumed acute myocardial infarction in the attempt to limit infarct size." | 7.66 | Intravenous propranolol therapy for acute myocardial infarction in man: hemodynamic and serial creatine kinase assessment. ( Cairns, JA; Klassen, GA, 1981) |
| " In intention-to-treat and per-protocol analyses, patients randomized to propranolol had worse pain scores on study days 5 to 19." | 5.20 | Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury. ( Bangdiwala, SI; Bortsov, AV; Cairns, BA; Haith, LR; Halawa, OI; Holmes, JH; Hoskins, JM; Hwang, J; Jones, SW; Jordan, MH; McLean, SA; Orrey, DC; Platts-Mills, TF; Roane, BR; Shupp, JW, 2015) |
| "Propranolol significantly decreased perceived intensity of heat pain stimuli but only in participants with small propranolol-induced blood pressure decreases." | 5.17 | Effects of intravenous propranolol on heat pain sensitivity in healthy men. ( Abulhasan, YB; Alhujairi, M; Balderi, T; Carli, F; Kim, DJ; Koeva, V; Schweinhardt, P, 2013) |
| "The number of patients reporting a reduction in pain intensity rating was greater during propranolol treatment (P=0." | 5.14 | Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. ( Diatchenko, L; Lim, PF; Maixner, W; McLean, SA; Slade, GD; Smith, SB; Tchivileva, IE, 2010) |
| "We studied usefulness of iontophoresis on pain relief using several Ca channel blockers, propranolol and guanethidine." | 3.68 | [Influence of calcium channel blockers and beta-blockers on pain relief with iontophoresis]. ( Honda, N; Ikebe, H; Miyagawa, A; Mizutani, A; Sendaya, K; Taniguchi, K; Yoshitake, S, 1992) |
| "Serum propranolol concentration, elimination t 1/2, and protein binding were studied after a combined intravenous/oral regimen in 20 subjects with myocardial infarction (MI) and 15 with chest pain (CP)." | 3.67 | Propranolol disposition after acute myocardial infarction. ( Norris, RM; Paxton, JW, 1984) |
| "Propranolol was administered intravenously to 12 patients with presumed acute myocardial infarction in the attempt to limit infarct size." | 3.66 | Intravenous propranolol therapy for acute myocardial infarction in man: hemodynamic and serial creatine kinase assessment. ( Cairns, JA; Klassen, GA, 1981) |
| " Mental stimulation or isoproterenol, and, respectively, pain or beta blockade induce changes of the repolarization phase divergent from steady state." | 3.65 | Stress-induced and sympathetically-mediated electrocardiographic and circulatory variations in the primary hyperkinetic heart syndrome. ( Fiorentini, C; Guazzi, M; Magrini, F; Olivari, MT; Polese, A, 1975) |
| "In 31 patients with at least 3 migraine attacks per month the prophylactic effect of tolfenamic acid 300 mg/day, propranolol 120 mg/day, and placebo was compared in a randomized double-blind cross-over study." | 2.66 | Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo. ( Christiansen, LV; Mikkelsen, B; Pedersen, KK, 1986) |
| "Propranolol pretreatment had no impact on analgesia from oral hydromorphone." | 1.72 | CYP2D in the brain impacts oral hydrocodone analgesia in vivo. ( Miksys, S; Novalen, M; Richards, J; Tyndale, RF, 2022) |
| "Pretreatment with propranolol or nor-BNI prior to restraint stress prevented both transient cutaneous allodynia and priming, demonstrated by a lack of umbellulone-induced cutaneous allodynia." | 1.62 | A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. ( Chessell, IP; Dodick, DW; Kopruszinski, CM; Navratilova, E; Porreca, F; Swiokla, J, 2021) |
| "Propranolol has anti-inflammatory effects that contribute to its antinociceptive action in the TMJ of females." | 1.48 | Anti-inflammatory effects of propranolol in the temporomandibular joint of female rats and its contribution to antinociceptive action. ( Dias, EV; Parada, CA; Sartori, CR; Tambeli, CH; Teixeira, JM; Zanelatto, FB, 2018) |
| "Erythromelalgia is a rare clinical syndrome characterized by erythema, increased temperature, and severe burning pain that can be aggravated by warmth or relieved by cold." | 1.42 | Erythromelalgia with a linear pattern in a 12-year-old girl. ( Choi, JY; Eun, LY; Huh, S; Jung, JW; Jung, MK, 2015) |
| "Propranolol is a non-selective β adrenergic receptor blocker which antagonises the anti-inflammatory effect of non-steroidal anti-inflammatory drugs via the β1 and β2 adrenergic receptors." | 1.37 | Effects of epinephrine and cortisol on the analgesic activity of metyrosine in rats. ( Akcay, F; Albayrak, Y; Karatay, S; Polat, B; Saglam, MB; Suleyman, H; Uslu, T; Yildirim, K, 2011) |
| "These arrhythmias occurred also with a short latency (mean 8." | 1.32 | Ventricular arrhythmias triggered by alerting stimuli in conscious rabbits pre-treated with dofetilide. ( Blessing, WW; De Pasquale, CG; Nalivaiko, E, 2004) |
| "The prognosis of treated hypochondriasis is good in a substantial proportion of patients." | 1.27 | Functional somatic symptoms and hypochondriasis. A survey of empirical studies. ( Kellner, R, 1985) |
| "The hyperthyroidism is self-limiting and should be treated conservatively." | 1.26 | Thyrotoxicosis with painless thyroiditis. ( Daly, R; Woolf, PD, 1976) |
| "The responsiveness of both migraine headaches and carotidynia to similar drugs suggests a common pathophysiologic mechanism." | 1.26 | Carotidynia. ( Prusiner, S; Raskin, NH, 1977) |
Research
Studies (80)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 50 (62.50) | 18.7374 |
| 1990's | 9 (11.25) | 18.2507 |
| 2000's | 4 (5.00) | 29.6817 |
| 2010's | 11 (13.75) | 24.3611 |
| 2020's | 6 (7.50) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Arguelles, N | 1 |
| Richards, J | 2 |
| El-Sherbeni, AA | 1 |
| Miksys, S | 2 |
| Tyndale, RF | 2 |
| Günay, Ç | 1 |
| Edem, P | 1 |
| Hız-Kurul, AS | 1 |
| Yaşar, E | 1 |
| Yiş, U | 1 |
| Cairns, BE | 1 |
| Novalen, M | 1 |
| Brignardello-Petersen, R | 1 |
| Kopruszinski, CM | 1 |
| Navratilova, E | 1 |
| Swiokla, J | 1 |
| Dodick, DW | 1 |
| Chessell, IP | 1 |
| Porreca, F | 1 |
| Zanelatto, FB | 1 |
| Dias, EV | 1 |
| Teixeira, JM | 1 |
| Sartori, CR | 1 |
| Parada, CA | 1 |
| Tambeli, CH | 1 |
| Hernández, CR | 1 |
| Loza, SM | 1 |
| López, RL | 1 |
| Del Mar García Romero, M | 1 |
| Kurauchi, Y | 1 |
| Haruta, M | 1 |
| Tanaka, R | 1 |
| Sasagawa, K | 1 |
| Ohta, J | 1 |
| Hisatsune, A | 1 |
| Seki, T | 1 |
| Katsuki, H | 1 |
| Tzeng, JI | 1 |
| Pan, HJ | 1 |
| Liu, KS | 1 |
| Chen, YW | 1 |
| Chen, YC | 1 |
| Wang, JJ | 1 |
| Orrey, DC | 1 |
| Halawa, OI | 1 |
| Bortsov, AV | 1 |
| Shupp, JW | 1 |
| Jones, SW | 1 |
| Haith, LR | 1 |
| Hoskins, JM | 1 |
| Jordan, MH | 1 |
| Bangdiwala, SI | 1 |
| Roane, BR | 1 |
| Platts-Mills, TF | 1 |
| Holmes, JH | 1 |
| Hwang, J | 1 |
| Cairns, BA | 1 |
| McLean, SA | 2 |
| Kline, RH | 1 |
| Exposto, FG | 1 |
| O'Buckley, SC | 1 |
| Westlund, KN | 1 |
| Nackley, AG | 1 |
| Huh, S | 1 |
| Jung, MK | 1 |
| Eun, LY | 1 |
| Jung, JW | 1 |
| Choi, JY | 1 |
| Light, KC | 1 |
| Bragdon, EE | 1 |
| Grewen, KM | 1 |
| Brownley, KA | 1 |
| Girdler, SS | 1 |
| Maixner, W | 2 |
| Tchivileva, IE | 1 |
| Lim, PF | 1 |
| Smith, SB | 1 |
| Slade, GD | 1 |
| Diatchenko, L | 1 |
| Cadirci, E | 1 |
| Suleyman, H | 2 |
| Hacimuftuoglu, A | 1 |
| Halici, Z | 1 |
| Akcay, F | 2 |
| Albayrak, Y | 1 |
| Saglam, MB | 1 |
| Yildirim, K | 1 |
| Karatay, S | 1 |
| Polat, B | 1 |
| Uslu, T | 1 |
| Schweinhardt, P | 1 |
| Abulhasan, YB | 1 |
| Koeva, V | 1 |
| Balderi, T | 1 |
| Kim, DJ | 1 |
| Alhujairi, M | 1 |
| Carli, F | 1 |
| Nalivaiko, E | 1 |
| De Pasquale, CG | 1 |
| Blessing, WW | 1 |
| Ferreira, J | 1 |
| Trichês, KM | 1 |
| Medeiros, R | 1 |
| Calixto, JB | 1 |
| Meerson, FZ | 1 |
| Medvedev, LN | 1 |
| Golubeva, LIu | 1 |
| Ustinova, EE | 1 |
| Kehlet, H | 1 |
| Sicuteri, F | 1 |
| Pantely, GA | 1 |
| Kloster, FE | 1 |
| Morris, CD | 1 |
| Paxton, JW | 1 |
| Norris, RM | 1 |
| Catania, A | 1 |
| Caimi, G | 1 |
| Jay, GW | 1 |
| Renelli, D | 1 |
| Mead, T | 1 |
| Ahmad, S | 1 |
| Areskog, NH | 1 |
| Bailey, RR | 1 |
| Saavedra, JM | 1 |
| Hollenberg, M | 1 |
| Budge, WR | 1 |
| Wisneski, JA | 1 |
| Gertz, EW | 1 |
| Nixon, JV | 1 |
| Hillert, MC | 1 |
| Shapiro, W | 1 |
| Smitherman, TC | 1 |
| Carstens, E | 1 |
| Zimmermann, M | 1 |
| Gay, JL | 1 |
| Nash, ML | 1 |
| Kunkes, SH | 1 |
| Pichard, AD | 1 |
| Smith, H | 1 |
| Gorlin, R | 1 |
| Herman, MV | 1 |
| Kupersmith, J | 1 |
| Cairns, JA | 1 |
| Klassen, GA | 1 |
| Koley, J | 1 |
| Basak, AK | 1 |
| Das, M | 1 |
| Sinha, S | 1 |
| Koley, B | 1 |
| Doak, GJ | 1 |
| Sawynok, J | 1 |
| Miao, FJ | 1 |
| Levine, JD | 1 |
| Ernberg, M | 1 |
| Lundeberg, T | 1 |
| Kopp, S | 1 |
| Woolf, PD | 1 |
| Daly, R | 1 |
| Madias, JE | 1 |
| Raskin, NH | 1 |
| Prusiner, S | 1 |
| Kopriva, CJ | 1 |
| Guinazu, A | 1 |
| Barash, PG | 1 |
| Plotnick, GD | 1 |
| Rainsford, KD | 1 |
| Oster, KA | 1 |
| Ross, DJ | 1 |
| Barg, IA | 1 |
| Lisnianskaia, RIa | 1 |
| Novikov, VT | 1 |
| Al'perovich, BR | 1 |
| Aranda, JM | 1 |
| Befeler, B | 1 |
| El-Sherif, N | 1 |
| Castellanos, A | 1 |
| Lazzara, R | 1 |
| Guazzi, M | 2 |
| Fiorentini, C | 2 |
| Polese, A | 2 |
| Magrini, F | 2 |
| Olivari, MT | 1 |
| Peng, YI | 1 |
| Liu, HJ | 1 |
| Guo, L | 1 |
| Fu, TC | 1 |
| Miyagawa, A | 1 |
| Taniguchi, K | 1 |
| Sendaya, K | 1 |
| Mizutani, A | 1 |
| Yoshitake, S | 1 |
| Ikebe, H | 1 |
| Honda, N | 1 |
| Olsen, UB | 1 |
| Lund, A | 1 |
| Foo, H | 1 |
| Westbrook, RF | 1 |
| Cunha, FQ | 1 |
| Lorenzetti, BB | 1 |
| Poole, S | 1 |
| Ferreira, SH | 1 |
| Miller, JF | 1 |
| Proudfit, HK | 1 |
| Albus, M | 1 |
| Zellner, A | 1 |
| Bondy, B | 1 |
| Müller-Spahn, F | 1 |
| Engel, R | 1 |
| Ackenheil, M | 1 |
| Wang, YJ | 1 |
| Wang, SK | 1 |
| Hough, LB | 1 |
| Glick, SD | 1 |
| Su, K | 1 |
| Kellner, R | 1 |
| Fujiwara, R | 1 |
| Orita, K | 1 |
| Bragin, EO | 1 |
| Nakamura, M | 1 |
| Lico, MC | 1 |
| Mikkelsen, B | 1 |
| Pedersen, KK | 1 |
| Christiansen, LV | 1 |
| Yu, GD | 1 |
| Chen, JS | 1 |
| Yin, WP | 1 |
| Yin, QZ | 1 |
| Zeng, WY | 1 |
| Kassirer, JP | 1 |
| Kopelman, RI | 1 |
| Dean, GA | 1 |
| Guidobono, F | 1 |
| Netti, C | 1 |
| Sibilia, V | 1 |
| Olgiati, VR | 1 |
| Pecile, A | 1 |
| Bory, M | 1 |
| Karila, P | 1 |
| Sainsous, J | 1 |
| Cohen, S | 1 |
| Djiane, P | 1 |
| Paulin, R | 1 |
| Serradimigni, A | 1 |
| Boakes, AJ | 1 |
| Prichard, BN | 1 |
| Lukasik, S | 1 |
| Wrabec, K | 1 |
| Nowosad, H | 1 |
| Vorherr, H | 1 |
| Yasue, H | 1 |
| Touyama, M | 1 |
| Shimamoto, M | 1 |
| Kato, H | 1 |
| Tanaka, S | 1 |
| Hanazono, N | 1 |
| Shimoyama, S | 1 |
| Ando, Y | 1 |
| Hilty-Tammivaara, R | 1 |
| Cullhed, I | 1 |
| Miasnikov, LA | 1 |
| Krasnikov, IuA | 1 |
| Nicotero, JA | 1 |
| Beamer, V | 1 |
| Moutsos, SE | 1 |
| Shapiro, AP | 1 |
Clinical Trials (6)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Analgesic Effects of Perioperative Propranolol Administration for Spine Surgery[NCT04421209] | Phase 2 | 0 participants (Actual) | Interventional | 2020-12-31 | Withdrawn (stopped due to No funding source) | ||
| Contribution of COMT Haplotypes in Propranolol Analgesic Efficacy for Treating Post-surgical Pain After Laparoscopic Hemicolectomy[NCT02511483] | Phase 2 | 10 participants (Actual) | Interventional | 2015-05-18 | Terminated (stopped due to Difficulty with recruitment) | ||
| The Effect of Sympathetic Dysfunction on Muscle Spindle Activity in Patients With Fibromyalgia Syndrome[NCT05704374] | 36 participants (Anticipated) | Interventional | 2023-11-02 | Not yet recruiting | |||
| Effect of COMT (Catecholamine-O-methyltransferase) Genetic Polymorphisms on Response to Propranolol Therapy in Temporomandibular Disorder[NCT02437383] | Phase 2 | 200 participants (Actual) | Interventional | 2015-08-20 | Completed | ||
| Genetic Variants Associated With the Occurrence of Localized Low Back Pain or Low Back Pain With Widespread Pain Symptoms, and Their Response to Treatment With Duloxetine or Propranolol[NCT03364075] | Phase 2 | 10 participants (Actual) | Interventional | 2017-09-01 | Terminated (stopped due to Recruitment issue) | ||
| The Serotonin Receptor Type 3 Antagonist Granisetron as a New Treatment Approach for Patients With Chronic Myofascial Pain in the Orofacial Muscles[NCT02230371] | Phase 4 | 40 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Change in Diastolic Blood Pressure After 9 Weeks of Treatment
Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Propranolol ER | -3.3 |
| Placebo | 1.0 |
Change in Heart Rate After 9 Weeks of Treatment
Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | beats per minute (Least Squares Mean) |
|---|---|
| Propranolol ER | -3.9 |
| Placebo | 1.5 |
Change in Maximum Assisted Jaw Opening After 9 Weeks of Treatment
Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | mm (Least Squares Mean) |
|---|---|
| Propranolol ER | -0.3 |
| Placebo | -0.8 |
Change in Maximum Unassisted Jaw Opening After 9 Weeks of Treatment
Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | mm (Least Squares Mean) |
|---|---|
| Propranolol ER | -0.9 |
| Placebo | -1.2 |
Change in Pain-free Jaw Opening After 9 Weeks of Treatment
Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | mm (Least Squares Mean) |
|---|---|
| Propranolol ER | 4.5 |
| Placebo | 1.4 |
Change in Pressure Pain Threshold at Lateral Epicondyle After 9 Weeks of Treatment
Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of lateral epicondyle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | kPa (Least Squares Mean) |
|---|---|
| Propranolol ER | 41.4 |
| Placebo | 22.7 |
Change in Pressure Pain Threshold at Masseter Muscle After 9 Weeks of Treatment
Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of masseter muscle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/- 7)
| Intervention | kPa (Least Squares Mean) |
|---|---|
| Propranolol ER | 38.3 |
| Placebo | 29.3 |
Change in Pressure Pain Threshold at Temporalis Muscle After 9 Weeks of Treatment
Pressure values, measured in kilopascals (kPa), from up to 5 experimental pressure stimuli, bilaterally applied to the area of temporalis muscle, are averaged to obtain a single pressure pain threshold value per anatomical site. The range is 0-500 kPa and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | kPa (Least Squares Mean) |
|---|---|
| Propranolol ER | 41.8 |
| Placebo | 38.4 |
Change in Pressure Pain Threshold at Temporomandibular Joint After 9 Weeks of Treatment
Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of temporomandibular joint, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | kPa (Least Squares Mean) |
|---|---|
| Propranolol ER | 36.8 |
| Placebo | 25.3 |
Change in Pressure Pain Threshold at Trapezius Muscle After 9 Weeks of Treatment
Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of trapezius muscle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | kPa (Least Squares Mean) |
|---|---|
| Propranolol ER | 64.1 |
| Placebo | 63.3 |
Change in Systolic Blood Pressure After 9 Weeks of Treatment
Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Propranolol ER | -3.6 |
| Placebo | 1.3 |
Change in the Headache Impact Test (HIT-6) Global Score After 9 Weeks of Treatment
"The HIT-6 contains 6 items and assesses headache-related disability by the frequency of daily activity limitations ranging from never to always. The 6 item scores are summed to yield a global score ranging from 36 to 78. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -5.1 |
| Placebo | -3.1 |
Change in the Hospital Anxiety and Depression Scale (HADS) Anxiety Score After 9 Weeks of Treatment
"The HADS is a 14-item assessment of anxiety (7 items) and depression (7 items) using the relative frequency of symptoms over the past week, rated on a 4-point scale ranging from 0 = not at all to 3 = very often indeed. Responses are summed to provide separate scores for anxiety and depression with a range from 0 to 21. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -1.3 |
| Placebo | -0.7 |
Change in the Hospital Anxiety and Depression Scale (HADS) Depression Score After 9 Weeks of Treatment
"The HADS is a 14-item assessment of anxiety (7 items) and depression (7 items) using the relative frequency of symptoms over the past week, rated on a 4-point scale ranging from 0 = not at all to 3 = very often indeed. Responses are summed to provide separate scores for anxiety and depression with a range from 0 to 21. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -1.0 |
| Placebo | -0.6 |
Change in the Jaw Functional Limitation Scale (JFLS) Global Score After 9 Weeks of Treatment
"The JFLS contains 20 items that measure limitations across mastication, vertical jaw mobility, and verbal/emotional expression rated on a 0-10 scale where 0 = no limitation and 10 = severe limitation. The Global Score is computed as the mean response for all items and ranges from 0 to 10. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -1.1 |
| Placebo | -0.8 |
Change in the Perceived Stress Scale (PSS) Global Score After 9 Weeks of Treatment
"The PSS assesses the frequency of 14 sources of stress on a scale from 0 = never to 4 = very often. The item scores are summed to yield a global score ranging from 0 to 56. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -2.6 |
| Placebo | -1.9 |
Change in the Pittsburgh Sleep Quality Index (PSQI) Global Score After 9 Weeks of Treatment
The PSQI has 19 items grouped into 7 component scores, each weighted equally on a 0-3 scale, The 7 component scores are summed to yield a global PSQI score, which has a range of 0-21. A higher score means a worse outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -0.7 |
| Placebo | -1.0 |
Change in the SF-12 Health Survey v2 (SF-12v2) Mental Component Summary (MCS) After 9 Weeks of Treatment
"The SF-12v2 contains 7 questions assessing 8 domains of functioning and well-being rated from: excellent to poor (for general health); yes, limited a lot to no, not limited at all (for functional level); and all of the time to none of the time (for emotional state). These 8 domains can be further summarized into a physical component summary (PCS) and a mental component summary (MCS). The range for each component is 0-100 and a higher score means a better outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | 3.6 |
| Placebo | 2.8 |
Change in the SF-12 Health Survey v2 (SF-12v2) Physical Component Summary (PCS) After 9 Weeks of Treatment
"The SF-12v2 contains 7 questions assessing 8 domains of functioning and well-being rated from: excellent to poor (for general health); yes, limited a lot to no, not limited at all (for functional level); and all of the time to none of the time (for emotional state). These 8 domains can be further summarized into a physical component summary (PCS) and a mental component summary (MCS). summary (MCS). The range for each component is 0-100 and a higher score means a better outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | 1.2 |
| Placebo | 0.3 |
Change in the SF-McGill Pain Questionnaire Affective Component After 9 Weeks of Treatment
"The SF-McGill Pain Questionnaire contains 4 affective descriptors rated on a 0-3 scale where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. The item scores are summed to yield a total score ranging from 0 to 12. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -2.9 |
| Placebo | -3.1 |
Change in the SF-McGill Pain Questionnaire Present Facial Pain Intensity After 9 Weeks of Treatment
"Self-reported present intensity of facial pain at the moment of assessment scored on a descriptive scale where 1 = no pain' and 6 = excruciating pain. A higher score means worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -0.9 |
| Placebo | -0.7 |
Change in the SF-McGill Pain Questionnaire Sensory Component After 9 Weeks of Treatment
"The SF-McGill Pain Questionnaire contains 11 sensory descriptors rated on a 0-3 scale where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. The item scores are summed to yield a total score ranging from 0 to 33. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -1.9 |
| Placebo | -1.6 |
Change in the SF-McGill Pain Questionnaire Weekly Average Facial Pain Duration After 9 Weeks of Treatment
"Self-reported average facial pain duration for the last week scored on 0-100 percentage scale where percent = percent of waking day you had facial pain. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -23.6 |
| Placebo | -21.6 |
Change in the SF-McGill Pain Questionnaire Weekly Average Facial Pain Intensity After 9 Weeks of Treatment
"Self-reported average facial pain intensity for the last week scored on 0-100 numerical rating scale where 0 = no pain and 100 = the most intense pain imaginable. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -18.2 |
| Placebo | -15.8 |
Change in the SF-McGill Pain Questionnaire Weekly Fatigue After 9 Weeks of Treatment
"Self-reported average fatigue for the last week scored on 0-100 numerical rating scale where 0 = no fatigue and 100 = the greatest imaginable. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -12.0 |
| Placebo | -11.4 |
Change in the Symptom Checklist 90-Revised (SCL-90R) Somatization Scale Score After 9 Weeks of Treatment
"The SCL-90R Somatization Scale is a 12-item assessment of somatic symptom distress over the past 7 days rated from 0 = not at all to 4 = extremely. The scale score is computed as the mean for all items. The score range is from 0 to 4. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -0.2 |
| Placebo | -0.2 |
Change in the Weekly Mean Pain Duration After 9 Weeks of Treatment
"Weekly mean pain duration computed as the arithmetic mean of daily pain duration values during the week prior to randomization and prior to each study visit. Daily pain duration is measured on 0-100 percentage scale where percent = percent of waking day you had facial pain as reported in the Daily Symptom Diary. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -17.9 |
| Placebo | -16.6 |
Change in the Weekly Mean Pain Index After 9 Weeks of Treatment
"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary and divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -13.9 |
| Placebo | -12.1 |
Change in the Weekly Mean Pain Intensity After 9 Weeks of Treatment
"Weekly mean pain intensity computed as the arithmetic mean of daily pain intensity values during the week prior to randomization and prior to each study visit. Daily pain intensity is measured on 0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) as reported in the Daily Symptom Diary. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -17.1 |
| Placebo | -13.6 |
Change in Thermal Pain Threshold After 9 Weeks of Treatment
Temperature values, measured in degrees Celsius, from 4 examiner-applied contact heat stimuli will be averaged to measure the experimental thermal pain threshold (temperature at which pain is first perceived). The range was 32-50 degrees Celsius and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | degrees Celsius (Least Squares Mean) |
|---|---|
| Propranolol ER | 1.3 |
| Placebo | 0.5 |
Change in Thermal Pain Tolerance After 9 Weeks of Treatment
Temperature values, measured in degrees Celsius, from 4 examiner-applied contact heat stimuli will be averaged to measure the experimental thermal pain tolerance (temperature at which pain can no longer be tolerated). The range was 32-50 degrees Celsius and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | degrees Celsius (Least Squares Mean) |
|---|---|
| Propranolol ER | 0.5 |
| Placebo | 0.4 |
Change in the Weekly Mean Pain Index After 9 Weeks of Treatment Stratified Per Number of COMT LPS Haplotypes
"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary, divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome. The pain index was stratified per number of catechol-O-methyltransferase (COMT) Low Pain Sensitive (LPS) haplotypes." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| 0 LPS haplotypes | 1 LPS haplotype | 2 LPS haplotypes | |
| Placebo | -12.3 | -13.2 | -2.5 |
| Propranolol ER | -14.2 | -12.2 | -15.2 |
Change in the Weekly Mean Pain Index After 9 Weeks of Treatment Stratified Per Number of COMT Valine Alleles at rs4680
"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary, divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome. The pain index was stratified per number of catechol-O-methyltransferase (COMT) valine alleles at single nucleotide polymorphism (SNP) rs4680." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| 0 valine alleles | 1 valine allele | 2 valine alleles | |
| Placebo | -13.9 | -13.1 | -9.7 |
| Propranolol ER | -14.2 | -13.9 | -14.3 |
Reviews
2 reviews available for propranolol and Ache
| Article | Year |
|---|---|
The contribution of autonomic mechanisms to pain in temporomandibular disorders: A narrative review.
Topics: Adrenergic Agonists; Analgesics; Antidepressive Agents; Autonomic Nervous System; Botulinum Toxins, | 2022 |
Opioid and catecholaminergic mechanisms of different types of analgesia.
Topics: Acetates; Acetic Acid; Acupuncture Therapy; Analgesia; Animals; Electric Stimulation; Electroshock; | 1986 |
Trials
9 trials available for propranolol and Ache
| Article | Year |
|---|---|
Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury.
Topics: Adrenergic beta-Antagonists; Adult; Burn Units; Burns; Catechol O-Methyltransferase; Double-Blind Me | 2015 |
Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.
Topics: Adrenergic beta-Antagonists; Adult; Cross-Over Studies; Double-Blind Method; Epinephrine; Female; Fi | 2009 |
Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.
Topics: Adrenergic beta-Antagonists; Adult; Cross-Over Studies; Double-Blind Method; Epinephrine; Female; Fi | 2009 |
Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.
Topics: Adrenergic beta-Antagonists; Adult; Cross-Over Studies; Double-Blind Method; Epinephrine; Female; Fi | 2009 |
Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.
Topics: Adrenergic beta-Antagonists; Adult; Cross-Over Studies; Double-Blind Method; Epinephrine; Female; Fi | 2009 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effects of intravenous propranolol on heat pain sensitivity in healthy men.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Affect; Blood Pressure; Double-Blind Method; Hot Tem | 2013 |
Late exercise test results from a prospective randomized study of bypass surgery for stable angina.
Topics: Adult; Angina Pectoris; Clinical Trials as Topic; Coronary Artery Bypass; Exercise Test; Female; Hum | 1983 |
Effect of propranolol and granisetron on experimentally induced pain and allodynia/hyperalgesia by intramuscular injection of serotonin into the human masseter muscle.
Topics: Adult; Double-Blind Method; Drug Combinations; Female; Granisetron; Humans; Hyperalgesia; Injections | 2000 |
Influence of CGP 361A, propranolol and diazepam on autonomous reactions to different stressors.
Topics: Adrenergic beta-Antagonists; Adult; Anxiety; Autonomic Nervous System; Blood Pressure; Diazepam; Dou | 1989 |
Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; | 1986 |
Effects of propranolol on the pressor response to noxious stimuli in hypertensive patients.
Topics: Adult; Blood Pressure; Cardiac Output; Cold Temperature; Epinephrine; Fatty Acids, Nonesterified; Fe | 1968 |
Other Studies
69 other studies available for propranolol and Ache
| Article | Year |
|---|---|
Sex, estrous cycle, and hormone regulation of CYP2D in the brain alters oxycodone metabolism and analgesia.
Topics: Analgesia; Analgesics, Opioid; Animals; Brain; Cytochrome P-450 Enzyme System; Estradiol; Estrous Cy | 2022 |
Recurrent painful ophthalmoplegic neuropathy: a report of two new pediatric cases.
Topics: Child; Child, Preschool; Female; Headache; Humans; Magnetic Resonance Imaging; Ophthalmoplegia; Opht | 2022 |
CYP2D in the brain impacts oral hydrocodone analgesia in vivo.
Topics: Analgesia; Analgesics, Opioid; Animals; Brain; Chromatography, Liquid; Cytochrome P-450 Enzyme Syste | 2022 |
Patients with temporomandibular pain who receive propranolol are more likely to experience pain reduction than those who receive a placebo.
Topics: Humans; Pain; Propranolol; Somatoform Disorders; Temporomandibular Joint Disorders | 2020 |
A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.
Topics: Animals; Calcitonin Gene-Related Peptide; Disease Models, Animal; Female; Hyperalgesia; Male; Mice; | 2021 |
Anti-inflammatory effects of propranolol in the temporomandibular joint of female rats and its contribution to antinociceptive action.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Analgesics; Animals; Anti-Inflammatory Ag | 2018 |
Red Ear Syndrome in a Pediatric Patient.
Topics: Adrenergic beta-Antagonists; Child; Diagnosis, Differential; Ear Diseases; Ear, External; Erythema; | 2018 |
Propranolol prevents cerebral blood flow changes and pain-related behaviors in migraine model mice.
Topics: Adrenergic beta-Antagonists; Animals; Cerebrovascular Circulation; Cortical Spreading Depression; Di | 2019 |
Epinephrine as adjuvant for propranolol produces a marked peripheral action in intensifying and prolonging analgesia in response to local dorsal cutaneous noxious pinprick in rats.
Topics: Adjuvants, Pharmaceutic; Analgesia; Anesthetics, Local; Animals; Behavior, Animal; Drug Synergism; E | 2014 |
Catechol-O-methyltransferase inhibition alters pain and anxiety-related volitional behaviors through activation of β-adrenergic receptors in the rat.
Topics: Adrenergic Agents; Analgesics; Animals; Anxiety; Catechol O-Methyltransferase; Catechol O-Methyltran | 2015 |
Erythromelalgia with a linear pattern in a 12-year-old girl.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Drug Therapy, | 2015 |
Indirect role of beta2-adrenergic receptors in the mechanism of analgesic action of nonsteroidal antiinflammatory drugs.
Topics: Adrenalectomy; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Analgesics; Animals; Anti- | 2010 |
Effects of epinephrine and cortisol on the analgesic activity of metyrosine in rats.
Topics: Adrenergic beta-Antagonists; alpha-Methyltyrosine; Analgesics; Animals; Carrageenan; Chromatography, | 2011 |
Ventricular arrhythmias triggered by alerting stimuli in conscious rabbits pre-treated with dofetilide.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Anti-Arr | 2004 |
Mechanisms involved in the nociception produced by peripheral protein kinase c activation in mice.
Topics: Adrenergic beta-Antagonists; Analgesics; Animals; Antibodies; Behavior, Animal; Blotting, Western; B | 2005 |
[Effect of emotional pain stress on Na, K-ATPase activity in the myocardium].
Topics: Adrenergic beta-Antagonists; Animals; Heart; Humans; Male; Myocardium; Pain; Propranolol; Rats; Rats | 1982 |
Should regional anesthesia and pharmacological agents such as beta blockers and opiates be utilized in modulating pain response?
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Alfentanil; Analgesia; Analgesics; Anesth | 1984 |
Inhibition of peptidase degrading endogenous opioids: a new trend in the management of migraine and correlated "pain diseases".
Topics: Brain; Captopril; Clonidine; Cluster Headache; Endorphins; Humans; Migraine Disorders; Nociceptors; | 1983 |
Propranolol disposition after acute myocardial infarction.
Topics: Administration, Oral; Adult; Aged; Chromatography, High Pressure Liquid; Hemodynamics; Humans; Injec | 1984 |
[Acute intermittent porphyria].
Topics: Acute Disease; Chlorpromazine; Diarrhea; Heme; Hemin; Humans; Intestinal Obstruction; Mitochondria, | 1983 |
The effects of propranolol and amitriptyline on vascular and EMG biofeedback training.
Topics: Adolescent; Adult; Aged; Amitriptyline; Biofeedback, Psychology; Female; Humans; Male; Middle Aged; | 1984 |
Phantom limb pain.
Topics: Aged; Humans; Male; Pain; Phantom Limb; Propranolol | 1984 |
Chest pain at exercise and coronary heart disease.
Topics: Coronary Disease; Exercise Test; Humans; Pain; Practolol; Propranolol; Thorax | 1981 |
Propranolol-induced acute interstitial nephritis.
Topics: Acute Disease; Humans; Male; Middle Aged; Nephritis, Interstitial; Pain; Propranolol | 1981 |
Spontaneously (genetic) hypertensive rats: naloxone-reversible and propranolol-reversible decrease in pain sensitivity.
Topics: Animals; Hypertension; Male; Naloxone; Pain; Propranolol; Rats; Rats, Inbred Strains; Sensory Thresh | 1981 |
Treadmill score quantifies electrocardiographic response to exercise and improves test accuracy and reproducibility.
Topics: Adult; Aged; Arterial Occlusive Diseases; Coronary Disease; Electrocardiography; Exercise Test; Fals | 1980 |
Submaximal exercise testing after unstable angina.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Coronary Disease; Exercise Test; Heart Rate; Humans; M | 1980 |
The opiate antagonist naloxone does not consistently block inhibition of spinal nociceptive transmission produced by stimulation in lateral midbrain reticular formation of the cat.
Topics: Afferent Pathways; Animals; Cats; Endorphins; Mesencephalon; Naloxone; Pain; Phentolamine; Propranol | 1980 |
Recurrent postpartum painless thyroiditis.
Topics: Adult; Female; Humans; Iodine Radioisotopes; Pain; Pregnancy; Propranolol; Puerperal Disorders; Recu | 1980 |
Silent ST segment deviations and extent of coronary artery disease.
Topics: Adult; Aged; Cardiac Catheterization; Coronary Disease; Electrocardiography; Female; Heart Rate; Hea | 1980 |
Intravenous propranolol therapy for acute myocardial infarction in man: hemodynamic and serial creatine kinase assessment.
Topics: Adult; Aged; Creatine Kinase; Female; Hemodynamics; Humans; Injections, Intravenous; Male; Middle Ag | 1981 |
Rectal response of cardiac origin in the cat: involvement of nitric oxide and acetylcholine.
Topics: Acetylcholine; Afferent Pathways; Animals; Arginine; Atropine; Blood Pressure; Cats; Coronary Vessel | 1997 |
Formalin-induced nociceptive behavior and edema: involvement of multiple peripheral 5-hydroxytryptamine receptor subtypes.
Topics: Animals; Edema; Formaldehyde; Indoles; Inflammation; Ketanserin; Male; Pain; Propranolol; Rats; Rats | 1997 |
Neural and endocrine mechanisms mediating noxious stimulus-induced inhibition of bradykinin plasma extravasation in the rat.
Topics: Adrenal Glands; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Bradykinin; Caps | 1999 |
Thyrotoxicosis with painless thyroiditis.
Topics: Adult; Antibodies; Female; Humans; Hyperthyroidism; Male; Middle Aged; Pain; Propranolol; Thyroid Fu | 1976 |
Recurrent chest pain with transient ST-segment elevation and acute myocardial infarction in a patient with normal coronary arteries.
Topics: Adult; Aspartate Aminotransferases; Coronary Angiography; Creatine Kinase; Electrocardiography; Huma | 1979 |
Carotidynia.
Topics: Adult; Aged; Carotid Artery Diseases; Dose-Response Relationship, Drug; Ergonovine; Female; Headache | 1977 |
Massive propranolol therapy and uncomplicated cardiac surgery.
Topics: Anesthetics; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Coronary Disease; Drug Interaction | 1978 |
Medical management of the patient with unstable angina.
Topics: Angina Pectoris; Diagnosis, Differential; Heart Rate; Humans; Myocardium; Oxygen Consumption; Pain; | 1978 |
The role of aspirin in gastric ulceration . Some factors involved in the development of gastric mucosal damage induced by aspirin in rats exposed to various stress conditions.
Topics: Animals; Arthritis, Experimental; Aspirin; Atropine Derivatives; Bethanechol Compounds; Cold Tempera | 1978 |
An enzyme mechanism in explanation of pain in angina pectoris.
Topics: Angina Pectoris; Animals; Bees; Enzyme Activation; Epinephrine; Humans; Nitroglycerin; Norepinephrin | 1975 |
[Differential diagnosis of ischemic heart disease and cardialgia by means of pharmacological tests in the polyclinical practice].
Topics: Adult; Ambulatory Care; Anti-Arrhythmia Agents; Coronary Disease; Diagnosis, Differential; Electroca | 1977 |
Mitral valve prolapse. Recent concepts and observations.
Topics: Animals; Arrhythmias, Cardiac; Blood Pressure; Cardiomyopathies; Coronary Circulation; Coronary Dise | 1976 |
Stress-induced and sympathetically-mediated electrocardiographic and circulatory variations in the primary hyperkinetic heart syndrome.
Topics: Adolescent; Adult; Atropine; Electrocardiography; Heart Diseases; Hemodynamics; Humans; Isoprotereno | 1975 |
Mechanisms of adrenaline-induced antinociception in mice.
Topics: Analgesics; Animals; Epinephrine; Injections, Spinal; Male; Mice; Mice, Inbred ICR; Naloxone; Pain; | 1992 |
[Influence of calcium channel blockers and beta-blockers on pain relief with iontophoresis].
Topics: Adult; Calcium Channel Blockers; Female; Guanethidine; Humans; Iontophoresis; Lidocaine; Male; Pain; | 1992 |
Inhibition by glutamate antagonists, MK-801 and NBQX, of cutaneo-cardiovascular pain reflex in rats.
Topics: Animals; Blood Pressure; Cardiovascular Physiological Phenomena; Cardiovascular System; Dizocilpine | 1991 |
Naloxone-induced hypoalgesia: effects of noradrenergic antagonists and agonist.
Topics: Animals; Clonidine; Hot Temperature; Male; Naloxone; Norepinephrine; Pain; Prazosin; Propranolol; Ra | 1991 |
Interleukin-8 as a mediator of sympathetic pain.
Topics: Animals; Atenolol; Benzazepines; Carrageenan; Dinoprostone; Edema; Foot; Guanethidine; Interleukin-1 | 1991 |
Antagonism of stimulation-produced antinociception from ventrolateral pontine sites by intrathecal administration of alpha-adrenergic antagonists and naloxone.
Topics: Adrenergic alpha-Antagonists; Animals; Dioxanes; Dopamine beta-Hydroxylase; Electric Stimulation; Fe | 1990 |
Effects of phentolamine and propranolol on the changes of pain threshold and contents of MEK and LEK in rat brain after EA.
Topics: Animals; Brain; Electroacupuncture; Enkephalin, Leucine; Enkephalin, Methionine; Male; Pain; Phentol | 1989 |
A role for histamine and histamine H2-receptors in non-opiate footshock-induced analgesia.
Topics: Animals; Cimetidine; Electroshock; Haloperidol; Histamine; Histamine H2 Antagonists; Male; Naloxone; | 1985 |
Functional somatic symptoms and hypochondriasis. A survey of empirical studies.
Topics: Anti-Anxiety Agents; Attitude to Health; Benzodiazepines; Conditioning, Psychological; Culture; Diag | 1985 |
The enhancement of the immune response by pain stimulation in mice. I. The enhancement effect on PFC production via sympathetic nervous system in vivo and in vitro.
Topics: Animals; Antibody Formation; Epinephrine; Hexamethonium Compounds; Immunoglobulin M; Male; Mice; Osm | 1987 |
Mechanism of peripheral pain in the conscious guinea pig: effect of propranolol.
Topics: Animals; Catecholamines; Evoked Potentials, Somatosensory; Guinea Pigs; Injections, Subcutaneous; No | 1986 |
[Effect of locus coeruleus stimulation on unit discharge of the hypothalamic arcuate nucleus in rats].
Topics: Animals; Arcuate Nucleus of Hypothalamus; Clonidine; Electric Stimulation; Electrophysiology; Hypoth | 1985 |
[Analgesic action of propranolol].
Topics: Analgesics; Animals; Clenbuterol; Mice; Pain; Propranolol; Rats; Sensory Thresholds | 1985 |
A surprising cause of abdominal pain, anorexia, vomiting, and weight loss.
Topics: Abdomen; Anorexia; Body Weight; Dexamethasone; Diagnosis, Differential; Drug Therapy, Combination; F | 1985 |
Mitral valve prolapse.
Topics: Adult; Arrhythmias, Cardiac; Dyspnea; Fatigue; Female; Heart Function Tests; Humans; Male; Mental Di | 1985 |
Role of catecholamines in calcitonin-induced analgesia.
Topics: Analgesics; Animals; Atenolol; Calcitonin; Catecholamines; Hydroxydopamines; Injections, Intraventri | 1985 |
[Simultaneous appearance of precordial pain and effort-induced left bundle branch block. A study of 6 patients with normal coronary angiography].
Topics: Adult; Atropine; Bundle-Branch Block; Coronary Angiography; Echocardiography; Exercise Test; Female; | 1985 |
The effect of AH 5158, pindolol, propranolol, D-propranolol on acute exercise tolerance in angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Butylamines; Dose-Response Relationship, Drug; Ethanol | 1973 |
[Qualification of patients with angina pectoris for beta-adrenolytic drug treatment].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Coronary Vessels; Humans; Myocardium; Oxygen Consumpti | 1974 |
Catecholamine antagonism to oxytocin-induced milk-ejection.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Animals; Blood Pressure; Catecholamines; Epinephrine; F | 1971 |
Role of autonomic nervous system in the pathogenesis of Prinzmetal's variant form of angina.
Topics: Adult; Angina Pectoris; Atropine; Blood Pressure; Coronary Vessels; Electrocardiography; Epinephrine | 1974 |
Clinical, electrocardiographic, and haemodynamic effects of long-term use of propranolol in Prinzmetal's variant angina pectoris.
Topics: Angina Pectoris; Arteries; Blood Pressure; Electrocardiography; Female; Follow-Up Studies; Heart Rat | 1971 |
A consideration on the mechanism of development of the attack of the variant form of angina pectoris.
Topics: Adult; Angina Pectoris; Blood Pressure; Catecholamines; Coronary Vessels; Dilatation; Electrocardiog | 1970 |
Exercise-released ventricular fibrillation in hypertrophic subaortic stenosis treated with propranolol. A case report.
Topics: Adult; Angina Pectoris; Aortic Valve Stenosis; Electrocardiography; Exercise Test; Female; Humans; P | 1970 |
[Symposium on the study of Inderal].
Topics: Angina Pectoris; Arrhythmias, Cardiac; Cardiovascular Diseases; Coronary Disease; Coronary Vessels; | 1967 |